Is it time for non-alcoholic fatty liver disease screening in patients with type 2 diabetes mellitus?

Giovanni Targher


Non-alcoholic fatty liver disease (NAFLD) has become one of the most important causes of chronic liver disease in Western countries (1). The increasing prevalence of this liver disease parallels the global epidemics of both obesity and type 2 diabetes (T2DM) in many parts of the world (1). NASH is also projected to become the most common indication for liver transplantation in the near future (1).

Article Options

Download Citation